Significance of Expression of Complement C4d in Esophageal Squamous Cell Carcinoma

被引：0

作者：

Kikuchi, Maiko ^{[1
]}

Nakajima, Masanobu ^{[1
]}

Muroi, Hiroto ^{[1
]}

Itoh, Masakazu Takahashi Jun ^{[1
]}

Itoh, Jun ^{[1
]}

Yamaguchi, Satoru ^{[1
]}

Sasaki, Kinro ^{[1
]}

Kato, Hiroyuki ^{[1
]}

机构：

[1] Dokkyo Med Univ, Dept Surg 1, 880 Kitakobayashi, Mibu, Tochigi 3210293, Japan

来源：

ANTICANCER RESEARCH | 2016年 / 36卷 / 09期

关键词：

Esophageal cancer; complement C4d; immune response evasion; immune tolerance; ACTIVATION PRODUCT C4D; OVARIAN-CANCER; LUNG-CANCER; INFLAMMATION; BIOMARKER; SYSTEM;

D O I：

10.21873/anticanres.11003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: Esophageal squamous cell carcinoma (ESCC) is one of the most difficult malignancies to cure. C4d is a degradation product of the classical complement pathway and is suggested as an early diagnostic marker for other SCCs. The purpose of this study was to clarify the association of complement C4d with ESCC. Patients and Methods: Immunohistochemical staining for C4d was performed on surgical specimens obtained from 114 patients with ESCC. Results: Positive C4d expression was observed in 70 (61.4%) cases and negative expression in 44 (38.6%) cases. There was a significant inverse correlation between C4d expression and depth of tumor invasion (p=0.0001), lymph node metastasis (p=0.011), lymphatic invasion (p=0.033), and TNM stage (p=0.0021). Kaplan-Meier analysis showed that negative C4d expression tended to lead to shorter overall survival (p=0.232). Conclusion: C4d expression in ESCC might be useful in developing treatment strategies or suppression of ESCC.

引用

页码：4553 / 4557

页数：5

共 24 条

[1] Complement activation product C4d in oral and oropharyngeal squamous cell carcinoma [J].

Ajona, D. ;

Pajares, M. J. ;

Chiara, M. D. ;

Rodrigo, J. P. ;

Jantus-Lewintre, E. ;

Camps, C. ;

Suarez, C. ;

Bagan, J. V. ;

Montuenga, L. M. ;

Pio, R. .

ORAL DISEASES, 2015, 21 (07) :899-904

[2] Investigation of Complement Activation Product C4d as a Diagnostic and Prognostic Biomarker for Lung Cancer [J].

Ajona, Daniel ;

Pajares, Maria J. ;

Corrales, Leticia ;

Perez-Gracia, Jose L. ;

Agorreta, Jackeline ;

Lozano, Maria D. ;

Torre, Wenceslao ;

Massion, Pierre P. ;

de-Torres, Juan P. ;

Jantus-Lewintre, Eloisa ;

Camps, Carlos ;

Zulueta, Javier J. ;

Montuenga, Luis M. ;

Pio, Ruben .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2013, 105 (18) :1385-1393

[3]

[Anonymous], 2009, TNM Classification of Malignant Tumours

[4] Inflammation and cancer: back to Virchow? [J].

Balkwill, F ;

Mantovani, A .

LANCET, 2001, 357 (9255) :539-545

[5] Harnessing the immune system to treat cancer [J].

Bhardwaj, Nina .

JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (05) :1130-1136

[6] Ascitic complement system in ovarian cancer [J].

Bjorge, L ;

Hakulinen, J ;

Vintermyr, OK ;

Jarva, H ;

Jensen, TS ;

Iversen, OE ;

Meri, S .

BRITISH JOURNAL OF CANCER, 2005, 92 (05) :895-905

[7] Pros and cons for C4d as a biomarker [J].

Cohen, Danielle ;

Colvin, Robert B. ;

Daha, Mohamed R. ;

Drachenberg, Cinthia B. ;

Haas, Mark ;

Nickeleit, Volker ;

Salmon, Jane E. ;

Sis, Banu ;

Zhao, Ming-Hui ;

Bruijn, Jan A. ;

Bajema, Ingeborg M. .

KIDNEY INTERNATIONAL, 2012, 81 (07) :628-639

[8] Anaphylatoxin C5a Creates a Favorable Microenvironment for Lung Cancer Progression [J].

Corrales, Leticia ;

Ajona, Daniel ;

Rafail, Stavros ;

Lasarte, Juan J. ;

Riezu-Boj, Jose I. ;

Lambris, John D. ;

Rouzaut, Ana ;

Pajares, Maria J. ;

Montuenga, Luis M. ;

Pio, Ruben .

JOURNAL OF IMMUNOLOGY, 2012, 189 (09) :4674-4683

[9] Inflammation and cancer [J].

Coussens, LM ;

Werb, Z .

NATURE, 2002, 420 (6917) :860-867

[10] Cancer immunoediting: from immunosurveillance to tumor escape [J].

Dunn, GP ;

Bruce, AT ;

Ikeda, H ;

Old, LJ ;

Schreiber, RD .

NATURE IMMUNOLOGY, 2002, 3 (11) :991-998

← 1 2 3 →